Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 31, 2022

SELL
$26.55 - $40.57 $192,089 - $293,523
-7,235 Closed
0 $0
Q3 2021

Oct 20, 2021

SELL
$39.27 - $72.94 $359,438 - $667,619
-9,153 Reduced 55.85%
7,235 $298,000
Q2 2021

Jul 20, 2021

SELL
$31.29 - $56.64 $4.89 Million - $8.86 Million
-156,362 Reduced 90.51%
16,388 $928,000
Q1 2021

Apr 22, 2021

SELL
$39.71 - $90.58 $40.6 Million - $92.6 Million
-1,022,658 Reduced 85.55%
172,750 $7.26 Million
Q4 2020

Feb 12, 2021

SELL
$27.07 - $84.35 $2.53 Million - $7.87 Million
-93,350 Reduced 7.24%
1,195,408 $83.8 Million
Q3 2020

Nov 06, 2020

BUY
$28.06 - $37.16 $4.64 Million - $6.14 Million
165,274 Added 14.71%
1,288,758 $36.2 Million
Q2 2020

Aug 14, 2020

BUY
$18.5 - $34.34 $1.73 Million - $3.21 Million
93,368 Added 9.06%
1,123,484 $33.2 Million
Q1 2020

May 13, 2020

BUY
$14.88 - $32.78 $880,285 - $1.94 Million
59,159 Added 6.09%
1,030,116 $20.4 Million
Q4 2019

Feb 12, 2020

BUY
$19.49 - $32.63 $664,628 - $1.11 Million
34,101 Added 3.64%
970,957 $28.8 Million
Q3 2019

Nov 20, 2019

BUY
$22.49 - $26.81 $1.73 Million - $2.06 Million
76,971 Added 8.95%
936,856 $21.3 Million
Q2 2019

Aug 14, 2019

BUY
$20.48 - $27.76 $3.24 Million - $4.39 Million
158,145 Added 22.54%
859,885 $21.3 Million
Q1 2019

May 13, 2019

BUY
$19.43 - $26.41 $3.53 Million - $4.8 Million
181,921 Added 35.0%
701,740 $17.4 Million
Q4 2018

Feb 14, 2019

BUY
$18.19 - $31.79 $321,599 - $562,047
17,680 Added 3.52%
519,819 $11.8 Million
Q3 2018

Oct 23, 2018

BUY
$27.65 - $38.39 $1.49 Million - $2.07 Million
53,991 Added 12.05%
502,139 $16 Million
Q2 2018

Aug 02, 2018

BUY
$31.4 - $41.01 $1.72 Million - $2.25 Million
54,850 Added 13.95%
448,148 $16.1 Million
Q1 2018

Apr 10, 2018

BUY
$29.84 - $44.08 $11.7 Million - $17.3 Million
393,298 New
393,298 $13 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $86.6M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Chevy Chase Trust Holdings, Inc. Portfolio

Follow Chevy Chase Trust Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chevy Chase Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Chevy Chase Trust Holdings, Inc. with notifications on news.